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Abstract
As cells replicate their DNA during mitosis, telomeres are shortened due to the inherent limitations of the DNA
replication process. Maintenance of telomere length is critical for cancer cells to overcome cellular senescence
induced by telomere shortening. Telomerase reverse transcriptase (TERT) is the rate-limiting catalytic subunit of
telomerase, an RNA-dependent DNA polymerase that lengthens telomeric DNA to maintain telomere homeostasis.
TERT promoter mutations, which result in the upregulation of TERT transcription, have been identified in several
central nervous system (CNS) tumors, including meningiomas, medulloblastomas, and primary glial neoplasms.
Furthermore, TERT promoter hypermethylation, which also results in increased TERT transcription, has been observed in ependymomas and pediatric brain tumors. The high frequency of TERT dysregulation observed in a variety of high-grade cancers makes telomerase activity an attractive target for developing novel therapeutics. In this
review, we briefly discuss normal telomere biology, as well as the structure, function, and regulation of TERT in
normal human cells. We also highlight the role of TERT in cancer biology, focusing on primary CNS tumors. Finally,
we summarize the clinical significance of TERT promoter mutations in cancer, the molecular mechanisms through
which these mutations promote oncogenesis, and recent advances in cancer therapies targeting TERT.
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One hallmark of cancer is the ability of cancer cells to replicate
indefinitely.1 This replicative potential runs counter to Hayflick’s
rule, which imposes a limit on the replicative potential of a
normal cell.2 This limitation is a result of the directionality of
DNA polymerase, which causes shortening of chromosome
ends after each replicative cycle, leading to cellular senescence.
The addition of telomeres to the ends of chromosomes allows
for successive replicative cycles without chromosomal DNA
shortening. Telomeres, which consist of noncoding TTAGGG
nucleotide repeats, protect the ends of chromosomes from deterioration and end fusion to other chromosomes.3,4 Telomeres
are protected from DNA damage by binding to proteins that
create a shelterin complex.4 The telomerase enzyme is an RNAdependent DNA polymerase that lengthens telomeric DNA to
maintain telomere homeostasis.5 Telomerase reverse transcriptase (TERT) is the rate-limiting catalytic subunit of telomerase.6

Telomerase activity is highly regulated. In most somatic
cells with finite proliferative potential, telomerase activity is
downregulated through epigenetic regulation of the TERT promoter.7,8 Telomeres in these somatic cells shorten with successive mitoses, ultimately triggering cellular senescence.9 In
contrast, in stem cells and proliferative cells of self-renewing tissues, telomerase activity is not downregulated and counteracts
the shortening of telomeres, allowing for increased replicative
potential.
Cancer cells must maintain telomere length to circumvent
cellular senescence. Telomerase upregulation can be found
in 90% of malignancies, although the mechanism of activation is not always known.9 One well-known mechanism,
upregulation of TERT transcription, often occurs through
TERT promoter mutations. Such mutations have been
found in meningioma, glioblastoma, medulloblastoma, and
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Normal Telomere Biology
Telomeres span approximately 10–20 kb at the end of
human chromosomes.3,4,18 The noncoding repeats in telomeres bind proteins that form the shelterin complex.3,4,18
Telomeres also consist of a 150–200 nucleotide, G-rich,
single-stranded overhang, which ends with a 3′-OH group
that is recognized by TERT.3,4 This single-stranded overhang
is protected from the DNA double-strand break repair machinery by folding back on itself to form the so-called T-loop
and by recruitment of the shelterin complex.3,18 The formation of this nucleoprotein structure protects chromosome
ends from nonhomologous end joining and regulates the
access of telomerase to telomeres.
Telomeres shorten with DNA replication due to an inability to fill in the gap with complementary DNA on the 5′end of the DNA strand after the RNA primer is removed
during replication, termed the “end replication problem.” 19
The loss of telomeric repeats with successive replication
cycles leads to an inability of the telomere to form the
T-loop or recruit the shelterin complex. This causes a loss
of chromosomal protection that leads to the formation of
end-to-end chromosomal fusions and loss of cell viability.3

A human telomere contains enough repeats to withstand
the loss of length for approximately 50–90 replication
cycles in the absence of telomere elongation mechanisms.4
Most cells undergoing continuous division, such as stem
cells, overcome the end replication problem by expressing
telomerase. The telomerase complex, which is comprised
of TERT and an RNA molecule encoded by the telomerase
RNA component (TERC) gene, binds to telomeres at
the end of the single-telomere overhang.3 Once TERT is
bound, its enzymatic activity elongates the telomere, thus
allowing the cell to undergo additional DNA replication
cycles (Figure 1).
Alternative lengthening of telomeres (ALT) is another
mechanism of telomere elongation. While most immortal
cell lines exhibit telomerase activity, some cell lines, including 10% of cancer lines, exhibit no telomerase activity
but still have elongated telomeres as a result of ALT.20
Although the details have not been elucidated, it is postulated that lengthening by ALT occurs by using recombination to copy telomeres from other chromosomes or from
the same chromosome.21,22 Whole exome sequencing of
glioblastomas with wildtype IDH and TERT promoter identified an ALT positive subgroup of tumors with ATRX or
SMARCAL1 mutations. These mutations are mutually exclusive and confer a similar overall survival to TERT promoter mutations, suggesting that ALT plays an important
role in glioblastoma.23
More recently, telomeres have been found to have
functions other than DNA end protection, such as regulation of gene expression through transcriptional silencing of genes.24 Although the mechanism is poorly
understood, the conformation of telomeric DNA, including structures such as the T-loop, is also thought to
contribute to telomere function. Additionally, RNA transcribed from telomeric DNA, so-called telomeric repeatcontaining RNA, has been implicated in a variety of
processes such as regulation of telomerase, heterochromatin organization at telomeres, and regulation of DNA
expression.4,24
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Fig. 1 Telomere elongation. After recruitment to the telomere by the shelterin complex, TERT catalyzes the addition of the telomere repeats
using the template provided by TERC. This counteracts the shortening of chromosomal telomeres in the setting of DNA replication.
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non-central nervous system (CNS) cancers.9–12 Another
well-described mechanism of TERT upregulation is TERT
promoter methylation, which paradoxically results in increased TERT expression in glioblastoma, ependymoma,
and medulloblastoma, along with several non-CNS
cancers.13–17
In this review, we outline normal telomere biology and
regulation of TERT. We discuss the mechanisms of TERT
upregulation and its role in cancer, focusing on glioblastoma and other CNS tumors. We also describe the clinical
and prognostic relevance of TERT mutations in CNS tumors. Finally, we discuss therapies that might target cancers with aberrant TERT upregulation.
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TERT Dysregulation in Cancer
TERT Promoter Mutations
Analysis of data from metastatic melanoma patients
by Huang et al.28 identified 2 recurrent C>T mutations in
the TERT promoter region -124 (C228T) and -146 (C250T)
base pairs from the transcriptional start site in 71% of patients. Subsequent screening for TERT promoter mutations found varying prevalence among different cancers
(Table 1).29 TERT promoter mutations are associated with
increased TERT expression and telomerase activity.10
Both commonly observed mutations (C228T and C250T)
generate identical de novo binding sites for the E-twentysix (ETS) family of transcription factors.28 Even though
there are 27 ETS transcription factors that all bind to similar sequences, only GA Binding Protein Transcription
Factor Subunit Alpha (GABPA) selectively binds the mutant TERT promoter and not the wildtype version in several cancers.9,30 GABPA functions as a homodimer or as
a heterotetramer with GABPB. The TERT promoter mutant
sites cooperate with native ETS sites to recruit GABPA/B
as a heterotetramer and activate TERT transcription.30 In
contrast, a study using melanoma cell lines found only
minimal binding of the GABPA homodimer to the mutant
TERT promoter.31

Table 1 Continued

TERT Promoter Mutations in CNS Neoplasms
TERT promoter mutations have been identified in CNS
tumors, including primary glial neoplasms (up to 80%),
medulloblastomas (20%), and meningiomas (6.4–11%).29,33–
40 As with other cancers, the 2 most common promoter
mutations are C228T and C250T, which occur in a mutually
exclusive fashion. The mutation frequency varies by subtype for each of these tumors.
In adult primary glial neoplasms, the frequency of TERT
promoter mutations varies by WHO grade (Figure 2).
Glioblastoma (WHO grade IV) has a high frequency of
mutations (80%). WHO grade II and III lesions, such as
oligodendrogliomas, have a relatively lower frequency of
TERT mutations (60–70%), and WHO grade I tumors, such
as astrocytomas, have the lowest frequency of TERT mutations (30–40%).29,33,37,39 In patients with primary glial
neoplasms, particularly glioblastoma, TERT promoter mutations were associated with co-mutations in epidermal
growth factor receptor (EGFR), CDKN2A/B, and phosphatase and tensin homolog.40 Data from multi-sector
sequencing of glioblastoma tumors revealed TERT promoter mutations to be clonal in all tumor sectors, suggesting that these mutations represent an early oncogenic
event in this cancer.41,42
In patients with meningiomas, TERT promoter mutations are associated with higher grade lesions (1.7% WHO
grade I, 5.7% WHO grade II, and 20% WHO grade III) and
with advancing tumor grade upon recurrence.35,38 In patients with medulloblastoma, although the overall mutation frequency is reported as 20%, the frequency of TERT
promoter mutations in the wingless (WNT) and sonic
hedgehog (SHH) subtypes has been reported to be as high
as 31% and 83%, respectively.33,36

TERT Promoter Hypermethylation
TERT promoter hypermethylation has more recently been identified as an additional contributor
to TERT dysregulation in cancer cells.13–17 Promoter
hypermethylation may represent an alternative means of
TERT upregulation or may work in conjunction with TERT
promoter mutations to increase TERT expression in cancer
cells. Hypermethylation of the promoter region would typically be expected to result in transcriptional silencing.
However, in the case of the TERT promoter, a region termed
the TERT hypermethylated oncological region (THOR) has
been identified as a site of methylation that causes an
increase in TERT expression when hypermethylated. THOR
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The TERT protein is comprised of 4 domains: the telomerase essential N-terminal domain (TEN), the reverse
transcriptase domain (RT), the telomerase RNA-binding
domain (TRBD), and the C-terminal extension domain.4,25 The TEN domain binds RNA and telomeric DNA
and contributes to catalysis.26 The RT domain contains
an insertion in the finger domain that distinguishes it
from other reverse transcriptases.25,26 TERT binds the
TERC-encoded RNA in the TRBD to form the telomerase
ribonucleoprotein.
TERT is located at chromosome 5p15.33 in humans,
while TERC is located at chromosome 3q26.24 TERC provides the template for synthesis of telomeric repeats,
whereas TERT is the catalytic component of telomerase.
The presence of TERT and TERC alone is sufficient for telomere elongation in vitro, but in vivo function also requires
other components that serve additional roles, such as
regulating attachment to telomeres and trafficking of telomerase components into the nucleus.4,24,27
The TERT gene is 40-kb long and consists of 15 introns and 16 exons with a 260-bp promoter core. The
TERT promoter region contains GC boxes that bind the
zinc finger transcription factor SP1, which increases TERT
transcription, and E-boxes that bind both transcriptional
enhancers and repressors.4,7,24 The GC-rich areas around
the transcription start site are also regions of epigenetic
regulation through DNA methylation and chromatin
remodeling.4

Neuro-Oncology
Advances

TERT Structure, Function, and
Regulation

Increased TERT transcription in the setting of TERT promoter mutation has also been found to occur in an NF-κβdependent manner. Unlike the C228T mutation, the C250T
mutation creates a binding site for the NF-κβ subunit p52,
allowing for the cooperative binding of NF-κβ and ETS1/2
to activate transcription.32 Thus, despite having similar
downstream effects, the 2 canonical TERT promoter mutations may distinctly alter TERT expression.  
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Table 1 Summary of the Frequency of TERT Promoter Mutations in
Central Nervous System Tumors
Mutation
Frequency
(%)

CNS cancers
Primary glioblastoma

70–80%12

Secondary glioblastoma

30–50%12

Astrocytoma

30–40%12

Oligoastrocytoma

35–55%12

Medulloblastoma

19.8%11

Meningioma
Ependymoma

7.4%11
3%12

Skin cancer—non-melanoma
Atypical fibroxanthoma

93%11

Pleomorphic dermal sarcoma

76%11

Squamous cell carcinoma

60%11

Basal cell carcinoma

47.4%11

Merkel cell carcinoma

10.2%11

Melanomas
Non-acral melanoma

35–80%12

Conjunctival melanoma

30–40%12

Mucosal melanoma

10–15%12

Acral melanoma

5–10%12

Uveal melanoma

0–1%12

Thyroid cancers
Poorly differentiated thyroid carcinoma

42.9%11

Anaplastic thyroid carcinoma

39.2%11

Follicular thyroid carcinoma

17.1%11

Atypical follicular thyroid adenoma

16.7%11

Hürthle cell carcinoma

13.1%11

Differentiated thyroid carcinoma

12.1%11

Papillary thyroid carcinoma

11.0%11

Gynecological cancers
Ovarian clear cell carcinoma

15.9%11

Squamous cell carcinoma of the cervix

9.9%11

Endometrial carcinoma

6.6%11

Ovarian low-grade serous carcinoma

4.9%11

Urological cancers
Micropapillary urothelial carcinoma
Squamous cell carcinoma of the bladder
 Infiltrating urothelial carcinoma with
glandular differentiation
Urothelial carcinoma

100%12
80%12
72%12
60–70%12

Renal pelvic carcinoma

45%12

Ureter carcinoma

19%11

Urethral carcinoma

15–20%12

Inverted urothelial papilloma

15%12

Chromophobe renal cell carcinoma

13%12

Clear cell renal cell carcinoma
Renal cell carcinoma, unclassified

5–10%12
8%12

Continued

Cancer Type

Mutation
Frequency
(%)

Digestive system cancers
 Combined hepatocellular
cholangiocarcinoma

45%12

Hepatocellular carcinoma

41.2%11

Gallbladder cancer

4%12

Intrahepatic cholangiocarcinoma

0–5%12

Esophageal squamous cell carcinoma

0–2%12

Gastric cancer

0%11

Pulmonary cancers
Malignant pleural mesothelioma
Lung and non-small cell lung carcinomas

15.2%11
0–2%11

Head and neck cancers
Laryngeal carcinoma

27.2%11

Squamous cell carcinoma of head and neck

16.3%11

Soft tissue cancers
Myxoid liposarcoma
Chondrosarcoma

69.4%11
50%†11

Fibrosarcoma

33.3%†11

Solitary fibrous tumor

24.1%11

†signifies

sample size less than 5.

  
is a 433-bp region that contains 52 CpG sites located immediately upstream of the TERT core promoter.17 Importantly,
hypermethylation of THOR results in increased TERT expression regardless of TERT promoter mutation status.
Furthermore, when THOR is unmethylated, the activating
effects of TERT promoter mutations appear to be repressed
compared to when THOR is hypermethylated.17 These findings suggest that THOR hypermethylation represents an independent mechanism of increased TERT expression from
TERT promoter mutations.
Remarkably, the frequency of THOR hypermethylation
may be as high as the frequency of TERT promoter mutations in some cancers. Indeed, more than 70% of prostate,
breast, hematological, and colon cancers are characterized by THOR hypermethylation.17 In general, the frequency of THOR hypermethylation appears to be greater
in cancers with a low frequency of TERT promoter mutations. Nonetheless, THOR hypermethylation has been
observed with relatively high frequency even in cancers
with a high frequency of promoter mutations and has
been found to be approximately 63% in CNS tumors.17

Impact of TERT Dysregulation in Cancer Cells
All cancer cells acquire molecular aberrations that confer
the properties of replicative immortality, sustained proliferative signaling, evasion of growth suppressors,
resistance to cell death, angiogenesis, invasion, and
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Cancer Type

  
Table 1
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Grade III

Grade IV

Oligodendroglioma
IDH mut, TERTp mut (72%)
IDH mut, 1p19q codel (71%)

IDH mut, TERTp mut (75%)
IDH mut, 1p19q codel (71%)

Astrocytoma

Precursor cell

IDH mut, TERTp wt (42–74%)
IDH wt, TERTp mut (6–28%)

IDH mut, TERTp wt (35–63%)
IDH wt, TERTp mut (19–30%)

IDH mut, TERTp wt (6–16%)
IDH wt, TERTp mut (54–74%)

Fig. 2 Frequency of TERT promoter mutation, IDH mutation, and 1p19q co-deletion in glioma. The frequency of TERT promoter mutations (TERTp
mut) increases with increasing grade of primary glial neoplasms. The presence of TERT promoter mutations in combination with other commonly
observed genetic abnormalities in gliomas, such as IDH mutation (IDH mut) and chromosome 1p19q co-deletion (1p19q codel), has both diagnostic and prognostic implications. Frequency of selected clinically relevant genomic co-alterations are shown here.33,43,44
  

metastasis.1,45 Telomere length plays a complex role in
oncogenesis. Critical shortening of telomeres results in
increased rates of oncogenic chromosomal alterations
such as deletions and chromosomal end fusions. At the
same time, the shortening of telomeres activates the
normal regulatory pathways that result in cellular senescence or even cell death. In 90% of cancers, telomerase
upregulation is critical to achieve proliferative immortality.4,20,24 The TERT subunit catalyzes the rate-limiting
step of telomerase, making the TERT gene a logical target
for upregulation in cancer cells. Indeed, Hahn et al.46
demonstrated that ectopic expression of TERT, in addition to key oncogene expression and tumor suppressor
dysfunction, is required for the transformation of human
somatic cells into tumorigenic cells.
Analysis of 1230 tumors from 60 cancer types by
Killela et al.29 found 2 distinct groups of cancers—those
with a high (≥15%) or a low (<15%) frequency of TERT
promoter mutations. The 9 cancers in the high-frequency
group all originated from tissues with low self-renewal
and included tumors such as medulloblastoma and primary gliomas. This finding led to the hypothesis that
TERT promoter mutations primarily benefit cancer cells
originating from tissues with low self-renewal potential.8 In cancers originating from the hematopoietic
system or gastrointestinal tract, for example, TERT promoter mutations would be predicted to have less of an
impact on TERT expression since these tissues already
express TERT. Accordingly, the frequency of TERT promoter mutations in these cancers is low.8,10,29 In contrast, cancers arising from cells with low replicative
potential that do not express TERT, such as astrocytes

or melanocytes, would gain a replicative advantage over
other cells via aberrant overexpression of TERT resulting
from promoter mutations.10,28,29,40,47 Although this explanation is corroborated by the relative frequency of these
mutations observed in several cancers, there are some
notable exceptions, including non-melanoma skin cancers, which have a high frequency, of TERT promoter
mutations.48 These exceptions suggest the possibility
that an oncologic advantage may be conferred through
alternative functions of the TERT protein or of telomeres
themselves.
Indeed, while TERT promoter mutations are associated
with increased telomerase expression in some cancers,
there is growing evidence that TERT promoter mutations
are not always associated with longer telomeres.39 In
human fibroblast cell lines that maintain long telomeres
through ALT, the expression of oncogenic H-RAS led to
inefficient tumorigenicity. However, overexpression of
TERT in addition to H-RAS resulted in robust malignant
transformation of ALT fibroblasts, suggesting that TERT
may have telomere-lengthening-independent roles in
tumor initiation and/or maintenance.49 Additionally, Chiba
et al.50 found that during malignant transformation in melanoma, TERT promoter mutation-driven telomerase expression does not prevent telomere shortening. Findings
such as these have led to the hypothesis that increased
telomerase expression may allow for the persistence of
genetically unstable clones by maintaining telomeres just
above a critically short length, thus avoiding cellular senescence while also promoting rapid disease evolution.
TERT may also have functions entirely independent
of telomere biology. For example, TERT is capable of
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Clinical Significance of Aberrant TERT
Expression
TERT promoter mutations occur in specific clinical and phenotypic subtypes of various cancers. They are found mainly
in adult rather than pediatric tumors and are sometimes
associated with more aggressively behaving subtypes of
cancers including melanomas, gliomas, meningiomas, and
hepatocellular carcinomas.4,33,38,40 Given the normal agedependent shortening of telomeres, it is unsurprising that
TERT promoter mutations are associated with increased
age at diagnosis for these cancers. The clinical impact of
these mutations has been most extensively studied in melanomas, where TERT promoter mutations were found to
be associated with markers of poor prognosis, such as increased Breslow thickness and metastasis, and with poor
overall survival and disease-free progression.4,29,47 The clinical impact of these mutations has similarly been studied in
primary CNS tumors, including gliomas and meningiomas.

Prognostic Impact of TERT Promoter Mutations
on Gliomas
Several genetic aberrations that modify prognosis have
been discovered in gliomas. Mutations in isocitrate dehydrogenase 1 (IDH1) are associated with lower histological grade, prolonged progression-free survival, and
increased response to chemoradiotherapy.58 These mutations tend to also be associated with secondary gliomas,
which progress from an antecedent lower grade to higher
grade disease.37,59 Meanwhile, 1p and 19q co-deletions
are associated with better survival in oligodendrogliomas
and also correlate with IDH1 mutations.60 Methylguanine
methyltransferase (MGMT) promoter methylation is yet
another critical determinant of prognosis and treatment response. Glioblastomas with MGMT promoter methylation

have been shown to have a more favorable treatment
response to alkylating agents with a resultant survival
benefit.61 The various combinations of these genetic abnormalities have identified subtypes of gliomas with clinically
distinct behavior. Factoring the presence of TERT promoter
mutational status into these combinations may allow for
better characterization of gliomas, with implications for
precision medicine.
TERT promoter mutation frequency increases with
increasing WHO grade in gliomas (Figure 2).29,37 Across all
subtypes of glioma, TERT promoter mutations are independently associated with worse overall survival.37,62,63 The
frequency of mutations is inversely correlated with IDH1
mutation in all gliomas but positively correlated with 1p
and 19q co-deletions in oligodendrogliomas.
The presence of TERT promoter mutations in combination with IDH1 mutations changes overall survival in glioma
patients. Gliomas with TERT promoter mutations without
IDH1 mutation have worse overall survival than those with
wildtype TERT promoter and IDH1 mutation. Meanwhile,
gliomas with wildtype TERT promoter and wildtype IDH1
have an intermediate overall survival. Paradoxically,
gliomas with both TERT promoter mutation and IDH1 mutation have improved overall survival compared to patients
with wildtype TERT promoter and IDH1 mutation.37,62,63
Interestingly, concomitant mutations in TERT and IDH1
occur at nearly the same frequency as concomitant mutations in IDH1 and 1p and 19q co-deletions, providing further
insight into the molecular etiology of oligodendrogliomas.64
Therefore, the improved survival in this group of patients
is not a result of biological interaction between these mutations but rather identification of a lower grade glioma.37,63
This is corroborated by the fact that the small group of
gliomas with co-mutations in TERT promoter and IDH1
without 1p and 19q co-deletions correspond to gliomas with
aggressive behavior and survival similar to those with TERT
promoter mutations and IDH1 wildtype.37,62,63
The important role of TERT promoter mutations on prognosis and clinical behavior is highlighted by the recently
published cIMPACT-NOW update 3, which recommends
that IDH wildtype grade II and III infiltrating astrocytomas
with TERT promoter mutations, EGFR amplification, and/or
chromosome 7 gain and 10 loss be graded as WHO grade
IV.65 Although not currently graded as WHO grade IV tumors, these tumors have clinical, histopathological, and
radiographic behavior similar to WHO grade IV tumors.63,66
Appropriate stratification of patients based on the genetic profile of their gliomas is thus critically important
in informing how aggressively they should be treated. To
this end, Shankar et al.67 developed a rapid intraoperative
genotyping assay to detect TERT promoter and IDH1
mutational status in WHO grade II and III gliomas. This
intraoperative molecular information has the potential to
aid in real-time surgical decision making and may allow for
precision therapy at the time of surgery.

Prognostic Impact of TERT Promoter Mutations
on Other Primary CNS Tumors
TERT promoter mutations are associated with higher
grade meningiomas.38 Across all grades of meningioma,
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performing RNA-dependent RNA polymerase (RdRP) functions via its association with BRG1, an SWI/SNF-related
chromatin remodeling protein, and nucleostemin, a GTPbinding protein, forming the TERT–BRG1–NS complex
(TBN complex). The TBN complex synthesizes doublestranded RNAs that are processed into short-interfering
RNAs that regulate heterochromatin assembly and mitotic
progression.51 Inhibitors targeting these non-canonical
functions of TERT serve as promising anticancer agents.
One such inhibitor, Eribulin, that targets the RdRP activity
of TERT is discussed in a later section.
Additionally, in an in vitro model, TERT knockout somatic cells were reprogrammed into pluripotent stem
cells by the introduction of an enzymatically inactive
TERT mutant, suggesting that TERT may maintain a
stem-like cell state independently of telomere lengthening.52 Potential mechanisms of this function include direct modulation of the Wnt/β-catenin signaling pathway
and increased EGFR expression.53,54 Finally, TERT may promote invasion and metastasis of cancer cells by altering
the expression of extracellular matrix remodeling and
epithelial-to-mesenchymal transition related genes.55–57

Patel et al. TERT, a promoter of CNS malignancies

The high frequency of TERT promoter mutations in cancers makes telomerase activity an attractive target for the
development of therapeutic interventions. Additionally,
normal cells typically have lower telomerase activity and
maintain longer telomeres than cancer cells, allowing

Mutant Promoter Inhibition

Inhibition of Telomere Elongation

  

Imetelstat
Imetelstat is the only small molecule inhibitor of TERT to
be evaluated in clinical trials.24 Imetelstat is a 13-bp RNA
oligonucleotide with a thio-phosphramidate backbone that
allows for the formation of RNA duplexes.68 The molecule
also contains a lipid moiety that increases cellular uptake
and retention.69 Unlike traditional antisense oligonucleotides, imetelstat was not designed to bind to mRNA but
rather to bind to TERT.24 In vitro studies demonstrated telomerase inhibition with concomitant telomere shortening
in several cell lines including tumors of the bladder, breast,
lung, liver, prostate, and pancreas. In vivo studies using
mouse xenograft lung cancer models showed similar results, in addition to reduced tumor growth and metastasis
and increased sensitivity to chemotherapy.24,70
In vitro studies of a glioblastoma cell line by Marian
et al.71 found that imetelstat produced a dose-dependent
inhibition of telomerase, with long-term treatment
leading to progressive telomere shortening, decreased
proliferation, and cell death in glioblastoma tumorinitiating cells. Furthermore, combining treatment with

RdRP Inhibition

Immunotherapy
Cancer cell

C228T
TERT Promoter

C250T
TERT

Imetelstat

TERT

TERT

Activated T cell

TERT

dsRNA

5´
GABPβIL
Tetramers

Eribulin

3´
hTERC

MHC

TCR

Fig. 3 Treatment strategies for TERT promoter mutant tumors. Various treatment strategies taking advantage of the presence of TERT promoter mutations have been proposed, including targeting the GABPβ1L tetramers that bind to the mutant promoter sites as transcription factors,
blocking the TERT active site using small molecule inhibitors such as Imetelstat that bind to TERC, inhibition of RNA-dependent RNA polymerase
(RdRP) activity with small molecule inhibitors such as Eribulin, and vaccine therapy targeting cells with increased TERT expression.
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TERT as a Therapeutic Target

cancer cells to be preferentially targeted by telomeraseinhibiting therapies. Despite this, there are challenges
to targeting TERT in the treatment of cancers. Telomere
shortening to a length that induces cell death requires
multiple cell cycles after TERT inhibition is initiated. This
results in a lag to the response of these therapies during
which time tumor burden increases. Furthermore, since
TERT is normally highly expressed in rapidly dividing
cells, targeting TERT can have side effects, particularly on
the hematopoietic system.24 One strategy to overcome
these challenges may involve the use of other, more immediately acting treatments in conjunction with TERTbased therapies.
To date, no FDA-approved treatments targeting telomerase are available, but approaches including use of small
molecule inhibitors, antisense oligonucleotides, immunotherapy, and G-quadruplex stabilizers are being investigated, with some therapies in various clinical trial
phases.24 Promising approaches to TERT targeting include
use of the small molecular inhibitor imetelstat (GRN163L),
immunotherapy, GABPβ1L inhibition, as well as targeting
RdRP activity of TERT using eribulin (Figure 3).
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the mutation has been associated with a more aggressive
natural history. Grade I tumors with the mutation were associated with a higher rate of recurrence with increased
risk of progression to a higher grade in recurrent tumors.
Analysis of recurrent meningiomas without malignant progression revealed a lack of the TERT mutation compared
to recurrent meningiomas with malignant progression.35
Similarly, grade II and III tumors with TERT mutations were
associated with higher recurrence rates as well as shorter
time to progression and/or recurrence.38,42 In high-grade
meningiomas, the TERT promoter mutation was associated with worse overall survival (2.7 years vs 10.8 years).42
The TERT promoter mutation is the most common
recurrent somatic point mutation observed in
medulloblastomas and occurs primarily in adults with
the SHH and WNT subtypes.34,36 The distribution of
promoter mutation frequency among the various subtypes of medulloblastoma is not surprising given that
the SHH subtype is the most common subtype in adult
medulloblastoma patients and, as observed with other
cancers, the mutation has a higher frequency among
older patients. Interestingly, unlike with other cancers,
TERT promoter mutations in SHH medulloblastomas are
associated with a more favorable overall survival and
with a lower incidence of metastatic disease on presentation. Group 4 medulloblastomas with the TERT promoter mutation follow the pattern observed in gliomas
and meningiomas, with worse overall survival than
those with wildtype TERT promoter.34 In the WNT and
group 3 medulloblastoma subtypes, the TERT promoter
mutation does not appear to make a difference in overall
survival. While the underlying biology explaining these
survival differences is poorly understood, stratification
of patients based on mutation status can inform discussions of prognosis and targeted therapeutics as they become available in the future.
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Immunotherapy
Cancer cells express protein fragments of telomerase
as cell surface antigens via the human leukocyte antigen
(HLA) class I pathway.73,74 These epitopes can be targeted
by cytotoxic T cells to kill cancer cells. The goal of antitelomerase immunotherapy is to sensitize the immune
system to tumor cells expressing TERT epitopes, resulting
in the activation of T cells.
One strategy used to achieve this goal is the development of TERT vaccines. Two vaccines have been used to
generate an anti-telomerase response in cancer cells:
GV1001 and Vx001. GV1001 is a 16-amino acid, HLA
class II-restricted peptide that contains a part of the
amino acid sequence of the TERT active site. Once injected, the vaccine is processed endogenously to yield
an HLA class I peptide as well. This vaccine therefore
activates a CD4+ and a CD8+ cellular response. Phase II
trials investigating GV1001 alone or in combination with
other therapies have been completed for malignant melanoma and hepatocellular carcinoma. Phase III GV1001
trials are ongoing for non-small cell lung carcinoma and
metastatic pancreatic cancer. Vx001 is a cryptic peptide
vaccine containing a TERT amino acid sequence hidden
within a protein structure. Endogenous processing of
the peptide results in the HLA class I presentation with a
CD8+ T-cell response. A phase 2 trial investigating Vx001
in non-small cell lung cancer is currently ongoing.
Another strategy is to prime antigen-presenting dendritic cells ex vivo and then inject the primed cells back into
the patient. GRNVAC1 is a dendritic cell vaccine consisting
of autologous dendritic cells transduced with mRNAencoding TERT and LAMP1, which guides TERT proteins
into lysosomes for breakdown and presentation. This results in a polyclonal immune response when the primed
dendritic cells are injected back into the patient. One phase
2 trial for GRNVAC1 in acute myelogenous leukemia has
been completed. All 3 TERT vaccines have been shown to
be well tolerated in cancer patients, with little effect on
normal cells and no autoimmunity.24

GABPβ1L Inhibition
Recently, Mancini et al.75 demonstrated that disruption of the β1L isoform of GABP reverses the replicative
immortality of glioblastoma cells in a TERT promoter

mutation-dependent manner. As previously discussed,
the C228T and C250T mutations allow specifically for the
binding of the heterotetramer form of the ETS transcription factor GABP.30 GABPβ1L is a tetramer forming isoform
of GABP that is not necessary for normal development
but binds to the mutant TERT promoter site. The authors
knocked down GABPβ1L in TERT promoter mutant glioblastoma cells in vitro, resulting in decreased GABP
binding, TERT expression, and cell viability. These effects
of GABPβ1L knockdown were not seen in wildtype TERT
promoter glioblastoma cells. Concordantly, knocking down
GABPβ1L in a mouse xenograft model of glioblastoma
impaired tumor growth and increased mouse survival.75
Targeting GABPβ1L rather than TERT itself may represent a means of specifically targeting tumor cells bearing
TERT promoter mutations while sparing normal cells, thus
avoiding the hematopoietic side effects observed with
drugs such as imetelstat.

Eribulin
Eribulin mesylate is a synthetic analog of halichondrin B,
a natural isolate from marine sponges and was originally
developed as an inhibitor of microtubule dynamics. In the
United States, it is approved for the treatment of refractory metastatic breast cancer in patients who have previously received 2 or more chemotherapeutic agents.76
Yamaguchi et al.77 demonstrated that eribulin inhibited
the growth of platinum-resistant ovarian cancer cells via
inhibition of the RdRP activity, a non-telomere lengthening role of TERT. In a xenotransplantation glioblastoma mouse model, intraperitoneal injection of eribulin
led to a significant reduction in intracranial tumor growth
demonstrating a promising role for this drug in glioblastoma treatment. A phase II trial in patients with recurrent
glioblastoma treated postoperatively with temozolomide,
radiation, and bevacizumab is currently ongoing in
Japan.78

Conclusions
Telomeres protect the ends of chromosomes from deterioration and end fusion to other chromosomes but shorten
with successive mitotic cycles in normal cells. In highly
replicative cells, the TERT expression maintains telomere
length. TERT expression is otherwise very tightly regulated
in normal somatic cells, with most cells silencing expression
and entering a senescent state as their telomeres shorten.
Two recurrent TERT promoter mutations have been detected in many cancers. In glioblastoma, meningioma, and
medulloblastoma, TERT promoter mutation frequency appears to increase with a worsening grade of tumor. In glioblastoma, the mutational frequency is particularly high
and the prognostic implications of the TERT mutation vary
depending on the presence of other mutations. The underlying biology explaining these survival differences is
poorly understood and warrants further investigation.
Nevertheless, the clinical significance of TERT mutation
highlights the importance of annotating its status in every
CNS tumor. Presently, therapies targeting TERT or telomere
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radiation and temozolomide reduced cancer cell survival
and enhanced activation of the DNA damage response
pathway. In vivo studies using mouse xenograft glioblastoma models revealed that imetelstat is able to cross the
blood-brain barrier with 70% inhibition of telomerase activity and reduced growth of subcutaneously implanted
tumors. While some imetelstat clinical trials have been
completed, some have been suspended due to hematological toxicity.24 A phase 2 clinical trial investigating
imetelstat use for recurrent pediatric primary glial neoplasms showed 95% inhibition of intratumoral telomerase activity, but also showed significant hematological
toxicity and was halted due to 2 patient deaths related to
intratumoral intracranial hemorrhage.72
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